«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

28卷

期数:

2022年02期

页码:

181-185

栏目:

临床医学

出版日期:

2022-03-20

文章信息/Info

Title:

Diagnosis and clinical significance of miR-24b-3p combined with miR-222-3p in urinary in prostate cancer

文章编号:

1006-8147(2022)02-0181-05

作者:

任超¹; 2

（1.天津医科大学人民医院临床学院，天津300121；2.天津市滨海新区大港医院检验科，天津300270）

Author(s):

REN Chao¹; 2

（1. Tianjin Union Medical Center，Tianjin Medical University，Tianjin 300121，China； 2. Department of Clinical Laboratory，Dagang Hospital of Tianjin Binhai New Area，Tianjin 300270，China）

关键词:

miRNAs; 前列腺癌; 生物标志物; qRT-PCR

Keywords:

miRNAs; prostate cancer; diagnostic biomarker; qRT-PCR

分类号:

R447

DOI:

-

文献标志码:

A

摘要:

目的：建立尿液miRNA检测板，作为诊断前列腺癌（PC）的无创性生物标志物。方法：采用miRNAs芯片分析对照1组（6名）及PC1组（18例）中miRNAs表达，并进一步利用qRT-PCR对20名对照2组及59例PC2组（GS2 6组22例，GS2 7组19例，GS28组18例）尿液、血清标本进行差异基因的进一步验证。应用受试者工作特征（ROC）曲线分析组合诊断模型的准确真实性。结果：获得在PC1组中20个miRNAs差异表达谱，与对照1组相比，miRNA-24-3p及miRNA-222-3p显著表达下调（T=5.79、4.59，均P＜0.05），用于PC诊断检测。在扩大样本量的PC患者尿液及血清样本中，根据GS分组的GS26、GS27及GS28组中，与对照2组相比，miRNA-24-3p联合miRNA-222-3p表达水平也都显著下调（t=3.89，P＜0.05），ROC分析联合诊断模型具有较高的准确度（曲线下面积为0.93，OR=1.37，95% CI：0.92~1.76，P＝0.02）。结论：在尿液、血清样本中建立了miRNA-24-3p联合miRNA-222-3p组合模型，可作为诊断PC的无创性生物标志物。

Abstract:

Objective： To establish a urine miRNA detection panel as a non-invasive biomarker helping diagnosing prostate cancer （PC）.Methods: A total of 18 PC1 group patients and 6 normal control group 1 urinary samples were analyzed through a miRNA microarray process，and further using quantitative real-time polymerase chain reaction，differentially expressed miRNAs were detected in urinary and serum of the PC2 patients（n=59），including 22 GS2 6，19 GS2 7 and 18 samples of GS2 8，20 normal samples as the control group 2.The accuracy and authenticity of the combined diagnostic model should be analyzed by the receiver operating characteristic（ROC）curve. Results: The differential expression profiles of 20 miRNAs in PC1 group were identified，including miR-24b-3p and miR-222-3p for PC detection，compared with control group1（T=5.79，4.59，all P＜0.05）. Moreover，in the urine and serum samples of PC samples with expanded samples，the expression of miR-24b-3p combined with miR-222-3p in GS6，GS7 and GS8 groups grouped according to GS score were significantly decreased than those in the control group 2（t=3.89，P<0.05）. The combined diagnostic model of ROC analysis has high accuracy（area under curve=0.93，OR=1.37，95% CI：0.92-1.76，P＝0.02）. Conclusion: A combined model of miR-24-3p and miR-222-3p in urinary and serum samples are established，which can be acted as a non-invasive biomarker helping diagnosing PC.

参考文献/References:

[1] KOMURA K，SWEENEY C J，INAMOTO T，et al. Current treatment strategies for advanced prostate cancer[J]. Int J Urol，2018，25（3）： 220-231.
[2] HEIDENREICH A，BELLMUNT J，BOLLA M，et al. EAU guidelines on prostate cancer. Part I：screening，diagnosis，and treatment of clinically localised disease[J]. Actas Urol Esp，2011，35（9）：501-514.
[3] KLOTZ L，ZHANG L，LAM A，et al. Clinical results of long-term follow-up of a large，active surveillance cohort with localized prostate cancer[J]. J Clin Oncol，2010，28（1）：126-131.
[4] HE L，HANNON G J. MicroRNAs：small RNAs with a big role in gene regulation[J]. Nat Rev Genet，2004，5（7）：522-531.
[5] KOZOMARA A，GRIFFITHS-JONES S.miRBase：annotating high confidence microRNAs using deep sequencing data[J]. Nucleic Acids Res，2014，42（Database issue）：D68-D73.
[6] HA M，KIM V N. Regulation of microRNA biogenesis[J]. Nat Rev Mol Cell Biol，2014，15（8）：509-524.
[7] MATSUZAKI K，FUJITA K，TOMIYAMA E，et al. MiR-30b-3p and miR-126-3p of urinary extracellular vesicles could be new biomarkers for prostate cancer[J]. Transl Androl Urol，2021，10（4）：1918-1927.
[8] SHIN S，PARK Y H，JUNG S H，et al. Urinary exosome microRNA signatures as a noninvasive prognostic biomarker for prostate cancer[J]. NPJ Genom Med，2021，6（1）：45.
[9] FABRIS L，CEDER Y，CHINNAIYAN A M，et al. The potential of micrornas as prostate cancer biomarkers[J]. Eur Urol，2016，70（2）： 312-322.
[10] FREDSOE J，RASMUSSEN A K I，THOMSEN A R，et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine[J]. Eur Urol Focus，2018，4（6）：825-833.
[11] LIU R S C，OLKHOV-MITSEL E，JEYAPALA R，et al. Assessment of serum microrna biomarkers to predict reclassification of prostate cancer in patients on active surveillance[J]. J Urol，2018，199（6）： 1475-1481.
[12] SUN Y，CHEN G，HE J，et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer[J]. Bioengineered，2021，12（1）：325-340.
[13] ANDERSEN C L，JENSEN J L，ORNTOFT T F. Normalization of real-time quantitative reverse transcription-PCR data：a model-based variance estimation approach to identify genes suited for normalization，applied to bladder and colon cancer data sets[J]. Cancer Res，2004，64（15）：5245-5250.
[14] FREDS?覫E J，RASMUSSEN A K I，MOURITZEN P，et al. A five-microRNA model（pCaP）for predicting prostate cancer aggressiveness using cell-free urine[J]. Int J Cancer，2019，145（9）：2558-2567.
[15] ZHANG S，LIU C，ZOU X，et al. MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer[J]. PeerJ，2021，9：e11441.
[16] LIN Y，CAO H，TIAN Y，et al. MiR-24-3p stimulates migration，invasion and proliferation of prostate cancer cells by targeting suppressor of cytokine signaling 6[J]. Int J Clin Exp Pathol，2018，11（3）： 1803-1810.
[17] LI X，HAN X，WEI P，et al. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1[J]. Cancer Biol Ther，2020，21（5）：452-462.
[18] KREBS M，SOLIMANDO A G，KALOGIROU C，et al. MiR-221-3p regulates VEGFR2 expression in high-risk prostate cancer and represents an escape mechanism from sunitinib in vitro[J]. J Clin Med，2020，9（3）：670-677.

相似文献/References:

[1]魏强,齐灿,罗飞,等.转移性去势抵抗性前列腺癌患者多西他赛化疗的预后分析[J].天津医科大学学报,2013,19(05):390.
[2]杨帮东,姜行康,齐 灿,等.尿液中PCA3评分对前列腺癌早期诊断的临床意义[J].天津医科大学学报,2013,19(06):487.
　YANG Bang-dong,JIANG Xing-kang,QI Can,et al.Clinical significance of urinary PCA3 score to diagnose prostate cancer[J].Journal of Tianjin Medical University,2013,19(02):487.
[3]刘利维,刘春雨. MicroRNAs 与前列腺癌的表观遗传学研究进展[J].天津医科大学学报,2014,20(01):74.
[4]王 超,余泉峰,徐 勇,等.经直肠超声造影诊断前列腺癌的临床分析[J].天津医科大学学报,2014,20(05):375.
　WANG Chao,YU Quan-feng,XU Yong,et al.Clinical analysis of contrast-enhanced transrectal ultrasonography for the diagnosis of prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):375.
[5]张晓会,张志宏,徐 勇,等.合并症对局限性或局部晚期前列腺癌患者早期生存的影响[J].天津医科大学学报,2014,20(05):379.
　ZHANG Xiao-hui,ZHANG Zhi-hong,XU Yong,et al. Influence of complications on early survival of patients with localized or locally advanced prostate cancer[J].Journal of Tianjin Medical University,2014,20(02):379.
[6]盛 镔,张 蒙,马鹏德,等.核糖体蛋白L37在前列腺癌中的表达及临床意义[J].天津医科大学学报,2015,21(05):401.
　SHENG Bin,ZHANG Meng,MA Peng-de,et al.Expression of ribosomal protein L37 in prostate cancer and its clinical significance[J].Journal of Tianjin Medical University,2015,21(02):401.
[7]管明秀,周云丽,王 萌,等.TuM2-PK，tPSA，fPSA/tPSA和PSAD对PSA灰区前列腺癌诊断价值的比较[J].天津医科大学学报,2016,22(02):140.
　GUAN Ming-xiu,ZHOU Yun-li,WANG-Meng,et al.Diagnostic implication of TuM2-PK, tPSA, fPSA/tPSA ratio and PSAD for prostate cancer in PSA gray area[J].Journal of Tianjin Medical University,2016,22(02):140.
[8]李 江,张恩龙,赵 阳,等.前列腺癌靶向磁共振成像和光热治疗的实验研究[J].天津医科大学学报,2017,23(02):93.
　LI Jiang,ZHANG En-long,ZHAO Yang,et al.?Experimental research of targeted magnetic resonance imaging and photo thermal therapy for prostate cancer [J].Journal of Tianjin Medical University,2017,23(02):93.
[9]张一然,潘盼,连振鹏,等.磁共振扫描对经直肠超声引导前列腺穿刺活检的影响[J].天津医科大学学报,2017,23(02):99.
　ZHANG Yi-ran,PAN Pan,LIAN Zhen-peng,et al.Effect of magnetic resonance imaging scan on the?transrectal ultrasound?prostate biopsy[J].Journal of Tianjin Medical University,2017,23(02):99.
[10]薄志强,孙桂江,王 丽,等.CtBP2异常表达对前列腺癌PC3细胞增殖效应影响的研究[J].天津医科大学学报,2017,23(02):103.
　BO Zhi-qiang,SUNGui-jiang,WANG Li,et al.Effect of abnormal expression of CtBP2 on the proliferation of prostate cancer cell line PC3[J].Journal of Tianjin Medical University,2017,23(02):103.

备注/Memo

备注/Memo:

作者简介 任超（1987-），女，技师，硕士在读，研究方向：临床检验诊断；通信作者：刘蕊，E-mail:renchao417@126.com。

常用功能

更新日期/Last Update: 2022-03-20